- Home
- PETS vs ELTX Comparison
PETS vs ELTX Comparison
Compare PETS & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- ELTX
- Stock Information
- Founded
- PETS 1996
- ELTX 2011
- Country
- PETS United States
- ELTX United States
- Employees
- PETS N/A
- ELTX N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- ELTX Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- ELTX Health Care
- Exchange
- PETS Nasdaq
- ELTX Nasdaq
- Market Cap
- PETS 82.0M
- ELTX 49.7M
- IPO Year
- PETS N/A
- ELTX 2021
- Fundamental
- Price
- PETS $3.98
- ELTX $4.78
- Analyst Decision
- PETS Sell
- ELTX Buy
- Analyst Count
- PETS 2
- ELTX 2
- Target Price
- PETS $3.50
- ELTX $10.00
- AVG Volume (30 Days)
- PETS 174.8K
- ELTX 14.0K
- Earning Date
- PETS 10-28-2024
- ELTX 11-07-2024
- Dividend Yield
- PETS 28.95%
- ELTX N/A
- EPS Growth
- PETS N/A
- ELTX N/A
- EPS
- PETS N/A
- ELTX N/A
- Revenue
- PETS $270,772,000.00
- ELTX N/A
- Revenue This Year
- PETS N/A
- ELTX N/A
- Revenue Next Year
- PETS $3.27
- ELTX N/A
- P/E Ratio
- PETS N/A
- ELTX N/A
- Revenue Growth
- PETS 2.26
- ELTX N/A
- 52 Week Low
- PETS $2.90
- ELTX $2.96
- 52 Week High
- PETS $10.53
- ELTX $11.45
- Technical
- Relative Strength Index (RSI)
- PETS 54.93
- ELTX 51.24
- Support Level
- PETS $3.89
- ELTX $4.39
- Resistance Level
- PETS $4.22
- ELTX $4.95
- Average True Range (ATR)
- PETS 0.20
- ELTX 0.26
- MACD
- PETS -0.02
- ELTX -0.01
- Stochastic Oscillator
- PETS 47.37
- ELTX 64.29
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.